Psoriatic arthritis (PsA) is a unique type of inflammatory arthritis associated with skin psoriasis. Given the diverse manifestations of PsA ranging from monoarticular, oligoarticular, small joint involvement, or axial involvement, this disease can be difficult to diagnose. Features of dactylitis and enthesitis are very useful in the diagnosis of PsA. In past decades, PsA, once considered to be a mild disorder, advances in psoriatic disease research have demonstrated this to be a progressive and destructive arthritis. The concept that PsA is simply a skin and joint disease has been challenged by large epidemiologic studies that link PsA with substantial important comorbidities including premature cardiovascular disease, infectious complications, malignancy risk, osteoporosis, and reduced health related quality of life. It is well known that elevated levels of TNF alpha are found both in the synovium as well as the skin of patients with PsA, and blockade with anti TNF therapy has led to attenuation of signs and symptoms of PsA. Although many rheumatologists are aware of the considerable overlap with rheumatoid arthritis, there are differences in pathophysiology and the approach to assessment and management are also important to take into account. This session will focus on the new advances in pathogenesis, early diagnosis, and therapeutic advances in patients with psoriatic arthritis.
Upon completion of this session, participants should be able to:
- review essential concepts in the diagnosis, assessment and management of psoriatic arthritis
- identify and manage significant comorbidities associated with psoriatic arthritis
- recognize the importance of multidisciplinary care of psoriatic arthritis patients
- discuss the recent advances in the treatment of patients with psoriatic arthritis
To see other sessions for this day, use the date buttons to the left.